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Tumor stroma-secreted growth factors, cytokines, and reactive oxygen species (ROS) influence 
tumor development from early stages to the metastasis phase. Previous studies have demonstrated 
downregulation of ROS-producing extracellular superoxide dismutase (SOD3) in thyroid cancer cell 
lines although according to recent data, the expression of SOD3 at physiological levels stimulates 
normal and cancer cell proliferation. Therefore, to analyze the expression of SOD3 in tumor stroma, 
we characterized stromal cells from the thyroid. We report mutually exclusive desmoplasia and 
inflammation in papillary and follicular thyroid cancers and the presence of multipotent mesenchymal 
stem/stromal cells (MSCs) in non-carcinogenic thyroids and papillary thyroid cancer (PTC). The 
phenotypic and differentiation characteristics of Thyroid MSCs and PTC MSCs were comparable with 
bone marrow MSCs. A molecular level analysis showed increased FIBROBLAST ACTIVATING PROTEIN, 
COLLAGEN 1 TYPE A1, TENASCIN, and SOD3 expression in PTC MSCs compared to Thyroid MSCs, 
suggesting the presence of MSCs with a fibrotic fingerprint in papillary thyroid cancer tumors and the 
autocrine-paracrine conversion of SOD3 expression, which was enhanced by cancer cells. Stromal SOD3 
had a stimulatory effect on cancer cell growth and an inhibitory effect on cancer cell migration, thus 
indicating that SOD3 might be a novel player in thyroid tumor stroma.
In solid tumors, paracrine factors secreted from the stroma regulate cancer cell growth and migration1–9. Reactive 
oxygen species (ROS), a well-known paracrine factor, contribute to stromal myofibroblast maturation10, thus 
emphasizing the effect of ROS in tumorigenesis. Extracellular superoxide dismutase (SOD3) has anti-oxidative, 
anti-inflammatory, anti-apoptotic, and growth promoting characteristics, exhibiting the most potent therapeutic 
responses and growth regulatory characteristics in cardiovascular and cancer models11–14,15–22. The expression of 
SOD3 is increased in a benign thyroid tumor goiter model and gradually downregulated in cell lines that model 
advanced papillary and anaplastic thyroid cancers correlating with the level of oncogene activation23,24. Of note, 
downregulation of growth stimulating SOD3 in epithelial cancer cells is controversial, particularly in light of 
recent data demonstrating SOD3-driven immortalization and even the transformation of murine primary cells, 
hence suggesting abrogation of the growth advantage in cancer cells23–28.
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In the current study, we describe mesenchymal stem cells (MSCs) isolated from non-carcinogenic thyroids 
(Thyroid MSCs) and papillary thyroid cancer (PTC MSCs), the latter showing desmoplastic characteristics. 
Importantly, a redox gene expression analysis showed downregulation of SOD3 in papillary thyroid cancer TPC1 
cells compared to Nthy control cells and upregulation in PTC MCS compared to Thyroid MSCs, hence suggesting 
autocrine-paracrine conversion of SOD3 mRNA expression. A functional analysis of stromal secreted SOD3 cor-
roborated previously published data20,26 showing increased cancer cell proliferation and decreased cell migration 
in co-culture. Therefore, our data suggest that the growth-promoting characteristics of SOD3 are not limited to 
the initial benign growth phase of tumorigenesis but are sustained to the end phase of tumor development.
Results
Histological analysis of papillary thyroid cancer and follicular thyroid cancer stroma sections. 
In thyroid cancers, desmoplastic stromal reactions, which correlate to lymph node metastasis, are a relatively 
common early phenomenon present in up to 80% of medullary thyroid cancers29. Characterization of papillary 
(PTC) and follicular (FTC) thyroid cancers 12 out of 20 cases (60%) demonstrated fibrosis or mononuclear cell 
infiltration. In PTC 40% of tumors showed desmoplastic regions and 30% inflammatory regions, whereas 40% of 
PTC tumors showed no detectable changes in stroma. In one case (10%) the stroma contained both desmoplas-
tic and inflammatory regions. Interestingly, 50% of the cases suggested mutual exclusion between fibrosis and 
inflammation (Fig. 1A–D and F–I). The analysis of FTC showed desmoplasia or mononuclear cell infiltration in 8 
out of 10 cases (80%). In seven cases (70%) there was mutual exclusion between fibrosis and inflammation: in five 
cases (50%) there was desmoplasia without inflammation and in two cases (20%) there was increased inflamma-
tion without fibrosis. In two cases (20%) there was no desmoplasia or inflammation, and in one case (10%) FTC 
stroma showed both desmoplasia and increased mononuclear cell content (Fig. 1E,J).
Mesenchymal stem cells from thyroid and papillary thyroid cancer. Most of the tissues have been 
suggested to contain multipotent mesenchymal stem/progenitor cells that support tissue renewal and function 
as a source of cytokines and growth factors30. To study the presence of MSCs in papillary thyroid cancer and a 
non-carcinogenic thyroid tissue counterpart, we isolated plastic adherent mesenchymal cells and characterized 
their phenotype. To test the stemness of the isolated cells, adipocyte, chondrocyte, and osteocyte lineage differ-
entiation assays were performed to define the multipotency of the isolated cells. We observed similar multipo-
tency among the bone marrow derived MSCs (BM MSC), the Thyroid MSCs, and the PTC MSCs, indicating 
the presence of mesenchymal stem cells in the adult thyroid tissues and papillary thyroid cancer tumor tissues 
(Fig. 2A–C). The analysis of the expression of cell surface cluster of differentiation (CD) molecules used to iden-
tify MSCs by flow cytometer suggested no differences among the BM MSCs, Thyroid MSCs, and PTC MSCs 
Figure 1. Representative histological images of hematoxylin-eosin staining of sections from papillary  
(A–D) and follicular (F–I) thyroid cancer. (A,B) Papillary thyroid cancer regions with desmoplastic stroma. 
(C,D) Papillary thyroid cancer regions with mononuclear cell infiltration. (E) Table showing papillary thyroid 
cancer patient numbers and the corresponding desmoplasia and/or inflammation. (F,G) Follicular thyroid 
cancer regions with desmoplastic stroma. (C,D) Follicular thyroid cancer regions with mononuclear cell 
infiltration. (E) Table showing follicular thyroid cancer patient numbers and the corresponding desmoplasia 
and/or inflammation. Calibration bars: 500 μ m (A,C,F,H); 100 μ m (B,D,G,I).
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(Fig. 2D), corroborating the differentiation data and suggesting the presence of mesenchymal stem cells similar 
to BM MSCs in thyroid and thyroid cancers.
Figure 2. Phenotypic assays for isolated BM MSCs, Thyroid MSCs, and PTC MSCs. (A) Adipocyte,  
(B) chondrocyte, and (C) osteocyte differentiation assays suggested no differences between BM-derived and 
thyroid-derived MSCs. (D) Flow cytometer analysis supported the differentiation data showing identical of 
cluster of differentiation (CD) expression in BM MSC, Thyroid MSC, and PTC MSC cell surfaces.
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PTC MSCs have fibrotic characteristics. Because our data showed the presence of fibrosis in papillary 
thyroid cancer, we studied desmoplastic molecular marker expression from Thyroid MSCs and PTC MSCs. 
Strikingly, in all five patients, PTC MSCs had higher FIBROBLAST ACTIVATING PROTEIN (FAP) mRNA 
expression compared to Thyroid MSCs. Similarly, PTC MSCs had significantly higher COLLAGEN 1 TYPE A1 
(Col1 A1) and TENASCIN mRNA expression levels as compared to Thyroid MSCs in four out of five and in three 
out of five patients, respectively. Although we observed variation in fibrotic marker expression in the patient 1 
(TENASCIN expression was at the level of controls), in the patient 2 (TENASCIN expression lower than in the 
controls), and in the patient 3 (Col1 A1 expression was at the level of controls) our data could suggest that mesen-
chymal stem cells may function as an origin for myofibroblasts (Fig. 3A–O).
SOD3 expression is reduced in epithelial cancer cells and is increased in MSCs with fibrotic char-
acteristics. Thyroid cancer progression and fibrosis correlate with increased reactive oxygen species (ROS) 
production and increased redox enzyme expression23,31. Hence, we investigated the gene expression of the super-
oxide dismutase SOD1-3 family and the NOX1-5 family from human immortalized Nthy thyroid cells modeling a 
normal thyroid and from papillary thyroid cancer patient-derived TPC1 cells. Comparable to our previous data26, 
we observed increased SOD2, NOX1, NOX2, and NOX5 mRNA expression in papillary thyroid cancer cells com-
pared to Nthy cell line. Importantly, we found decreased expression of SOD3 recurrently with recent works23,26 
and an absence of NOX4 expression (Fig. 4A).
The redox gene expression patterns of Thyroid MSCs compared to PTC MSCs were similar to the expressions 
observed in thyroid epithelial Nthy and TPC1 cells, with the exceptions of SOD3 and NOX4. The NOX4 gene 
was undetectable in the epithelial Nthy and TPC1 cells, whereas Thyroid MSCs and PTC MSCs both had high 
NOX4 expression levels. Analysis of SOD3 mRNA demonstrated increased expression in PTC MSCs compared 
to in Thyroid MSCs, thus suggesting autocrine-paracrine conversion of SOD3 mRNA synthesis (Fig. 4B). To 
confirm the increased SOD3 levels in the PTC MSCs, we analyzed the mRNA expression of the enzyme from each 
patient and determined the stimulatory effect of TPC1 cancer cell condensed medium on SOD3 mRNA levels. 
Interestingly, the mRNA production was significantly increased in all five samples of patient-derived PTC MSCs 
compared to their Thyroid MSC counterparts (Fig. 4C–G), which was shown to be enhanced by TPC1 paracrine 
action (Fig. 4F,G).
Paracrine MSC secreted SOD3 increases epithelial cancer cell growth. According to previous data, 
BM MSCs could reduce cancer cell proliferation via the paracrine system, thereby inhibiting tumorigenesis32. On 
the contrary, tumor-associated stromal cells, such as tumor-associated fibroblasts and mesenchymal stem cells, 
have been shown to promote cancer cell proliferation and tumor growth33,34. Therefore, we tested the growth 
stimulating properties of Thyroid MSCs and PTC MSCs on the papillary thyroid cancer TPC1 cell line. In line 
with previous reports, a BrdU DNA incorporation assay for TPC1 papillary thyroid cancer cells cultured together 
with Thyroid MSCs suggested decreased DNA replication, whereas cancer cells grown in the presence of PTC 
MSCs showed significantly increased BrdU incorporation (Fig. 5A,B).
To probe the paracrine effect of SOD3 expression on cancer cell growth, we over-expressed SOD3 in Thyroid 
MSCs (Thyroid MSC SOD3) and silenced the gene expression by SOD3 RNAi in PTC MSCs (PTC MSC SOD3 
RNAi) (Fig. 5C,D). Co-culture of TPC1 cells with Thyroid MSC SOD3 suggested significantly (p < 0.01) increased 
DNA replication of TPC1 cells compared to the parental Thyroid MSCs (Fig. 5E,F). Correspondingly, RNAi 
SOD3 treatment of PTC MSCs decreased (p < 0.001) TPC1 DNA replication compared to parental PTC MSCs 
(Fig. 5G,H), thus demonstrating that PTC MSCs may support cancer cell growth by secreting SOD3.
SOD3 has been demonstrated to regulate the activation of a large number of growth-related signaling molecules14,27. 
We then studied the growth factor gene expression in Thyroid MSC SOD3 and PTC MSC SOD3 RNAi cells. 
The analysis revealed correlations among SOD3, FIBROBLAST GROWTH FACTOR 9 (FGF9), and BONE 
MORPHOGENIC PROTEIN 2 (BMP2) expression (Fig. 5I,J).
Paracrine effect of SOD3 on epithelial cancer cell migration. Desmoplastic thyroid tumors fre-
quently metastasize to the lymph nodes29, suggesting increased intratumoral cancer cell migration toward the 
lymphatic vasculature. In the current work, the Matrigel migration analysis demonstrated significantly (p < 0.001) 
increased TPC1 migration levels towards Thyroid MSCs compared to PTC MSCs (Fig. 6A), which may indicate a 
lower affinity of TPC1 cells to tumor stroma. The analysis of the effect of SOD3 on TPC1 cell migration showing 
significantly (p < 0.01) reduced migration toward SOD3 over-expressing Thyroid MSCs (Thyroid MSC SOD3) 
(Fig. 6B) could suggest regulation of local cancer cell migration by paracrine secretion of the enzyme. However, 
silencing of SOD3 in PTC MSCs (PTC MSC SOD3 RNAi) failed to show increased cancer cell migration (Fig. 6C), 
indicating that SOD3 might have a different function in fibrotic MSCs or that the activation process of PTC MSCs 
modifies the ROS balance, hence altering the effect of single redox genes.
Previous publications have proposed that inflammatory and cancer cell migration are regulated by the same 
chemoattractants35,36. We recently demonstrated SOD3-derived decreased expression of TNFα, IL1α, IL6, MIP2, 
and MCP-1 inflammatory cytokines in cardiovascular models with consequent inhibition of monocyte/mac-
rophage migration17,20,37. The expression analysis of IL1α, MCP-1, and IL8 showed reduced cytokine expression 
in PTC MSCs compared to Thyroid MSCs (Fig. 6D–J). The data, however, suggest that only IL1α and MCP-1 
are downregulated by SOD3 in stromal cells (Fig. 6D,E), whereas IL8 expression is independent of the enzyme 
(Fig. 6F). Western blot analysis for MCP-1 (Fig. 6G) and flow cytometer analysis for IL8 (Fig. 6H,I) supported the 
mRNA expression data showing decreased expression in PTC MSCs compared to Thyroid MSCs. Our current 
data thus support our previous observations demonstrating that SOD3 stimulates cell proliferation and inhibits 
cell migration17,18,20,23–28,37,38.
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Figure 3. Expression analysis of FAP, Col1A1, and TENASCIN desmoplastic markers in Thyroid MSCs and 
PTC MSCs. (A–O) The qRT-PCR data demonstrated significantly increased desmoplastic marker expression  
in all five patient-derived PTC MSC samples compared to their non-carcinogenic thyroid counterparts.  
(A–C) Patient 1, (D–F) Patients 2, (G–I) Patient 3, (J–L) Patient 4, and (M–O) Patient 5. The p-values 
(*p < 0.05, **p < 0.01, ***p < 0.001) were determined by two-tail independent samples t-tests.
www.nature.com/scientificreports/
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Discussion
Local vascular permeability with consequent extravasation of fibrinogen and plasminogen initiate the formation of 
fibrin gel deposits, the early form of tumor stroma, which attracts migrating fibroblasts, epithelial cancer cells and 
inflammatory cells. Importantly, continuous tumor growth creates a demand for continuous stroma expansion. 
Thus, tumor stroma has different developmental stages that affect cancer cells, regulating their proliferation and 
local migration. According to recent data, the development of stroma is connected to the progression of carcino-
genesis, such as lymph node metastasis39, indicating that stroma responds to the microenvironmental needs of 
epithelial cancer cells through paracrine growth factor secretion and direct cell-to-cell contact40–42. Additionally, 
activated desmoplastic stroma, which is frequently observed in medullary thyroid cancers, is used as a clinical 
intraoperative diagnostic marker to characterize tumor progression and to predict lymph node metastasis29,39,43,44. 
In the present work, we observed a marked inverse correlation between desmoplasia and inflammatory cell infil-
tration in PTC and FTC: 12 out of 20 patients had increased desmoplasia or increased mononuclear cell infil-
tration, whereas only two out of 20 patients had simultaneous desmoplasia and inflammation (Fig. 1). Previous 
articles have suggested that aggressive cancers, such as pancreatic ductal adenocarcinoma characterized by an 
excessive stromal reaction, may have reduced intratumoral vascularization45 that could cause reduced mononu-
clear cell migration into desmoplastic tumors. However, in a recent work the immunohistochemical analysis of 
fibroblast activating protein α -positive medullary thyroid carcinomas showed no correlation between new vessel 
formation and stromal fibrosis29, thus indicating other mechanisms than the physiological fibrotic barrier in the 
inhibition of cell migration. Inflammation has also been suggested to precede fibrosis development: infiltrated 
inflammatory cells secrete profibrogenic cytokines that affect fibroblast activation, perivascular fibrosis develop-
ment, and cellular migration46,47.
An interesting, although rare, characteristic of thyroid tumors is intratumoral heterotopic ossification48–54, 
which may suggest the presence of multipotent mesenchymal stem/stromal cells in thyroid tissue. Indeed, 
tumor-associated MSCs recently characterized in ovarian carcinoma and prostate cancer have similar phenotype 
and functionality as BM MSC but altered growth factor expression profile55,56. The current data, which demon-
strate the presence of MSCs in non-carcinogenic thyroid and papillary thyroid cancer with a similar differenti-
ation capacity and CD marker expression as BM MSCs (Fig. 2) strengthening the previous observations, could 
further indicate that MSCs maintain their stemness even in conditions where they are under constant external 
carcinogenic stimuli. However, a more accurate gene expression analysis of fibrotic markers in Thyroid MSCs 
and PTC MSCs (Fig. 3) showed differentiation stage-related differences that affected functional properties, such 
as proliferation (Fig. 5A) and migration (Fig. 6A), in neighboring cells. We demonstrated that PTC MSCs had 
increased expression of fibrotic markers (Fig. 3). Although MSC cultures in general are heterogeneous containing 
cells with various degrees of differentiation, the current data may suggest that tumor stroma MSCs exposed to 
Figure 4. Gene expression of SOD1-3 and NOX1-5 in thyroid cells. We used Nthy cells modeling normal 
thyroid epithelia, TPC1 cells modeling papillary thyroid cancer, Thyroid MSCs, and PTC MSCs. (A) SOD1, 
SOD2, NOX1-3 and NOX5 showed increased expression levels in TPC1 cells compared to in the Nthy cell  
line, whereas SOD3 expression was downregulated in the TPC1 cells. NOX4 expression was not detectable.  
(B) SOD1, SOD2, NOX1-3, and NOX5 expression levels in the PTC MSCs were increased or remained at the 
same level as in the Thyroid MSCs. SOD3 expression was significantly higher in the PTC MSCs compared to  
in the Thyroid MSCs. There was high NOX4 expression in both the Thyroid MSCs and the PTC MSCs.  
(C–G) Increased SOD3 mRNA synthesis was confirmed in each of the five patients. (F,G) Expression analysis 
using TPC1-condensed medium suggested a cancer-derived paracrine effect in SOD3 activation. The p-values 
(*p < 0.05, **p < 0.01, ***p < 0.001) were determined by two-tail independent samples t-tests.
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cancer cell secretion could obtain similar phenotypic characteristics as cancer associated fibroblasts and therefore 
serve as an origin of cells for activated fibroblasts.
ROS have been demonstrated to contribute to carcinogenesis and myofibroblast differentiation. Interestingly, 
NOX4 expression, which is absent in thyroid cancer cells26 (Fig. 4), was observed in MSCs, which may suggest a 
paracrine role for the protein in the thyroid. Furthermore, SOD3 expression suggested autocrine-paracrine con-
version from epithelial cancer cells to mesenchymal stromal cells (Fig. 4), which could shed light on the function 
of SOD3 in tumorigenesis. Previous data have shown increased SOD3 expression in an experimental rat thyroid 
goiter model23 with corresponding growth-supporting function at physiological expression levels14,18,25,26,28,57. A 
strong connection of SOD3 to growth regulation is caused by positive a feedback loop between the enzyme, 
small GTPase activation, and RAS-ERK1/2 signaling24,25,27,28. Moderately increased small GTPase RAS activation 
stimulates SOD3 mRNA synthesis, but at aberrant levels of RAS activity (> 10-fold RAS activation level), there is 
Figure 5. Paracrine effect of SOD3 on TPC1 cancer cell growth. (A,B) TPC1 cell growth in Thyroid MSC 
and PTC MSC co-cultures suggested significantly decreased TPC1 DNA replication in the Thyroid MSC culture 
and significantly increased DNA replication in the PTC MSC co-culture. (C) SOD3 expression in Thyroid 
MSCs and Thyroid MSCs transduced with SOD3 lentivirus. (D) SOD3 expression in PTC MSCs and PTC MSCs 
transduced with RNAi SOD3 lentivirus. (E,F) TPC1 DNA replication in Thyroid MSCs and Thyroid MSCs 
transduced with SOD3 lentivirus suggested increased SOD3-driven TPC1 growth. (G,H) RNA interference of 
SOD3 in PTC MSCs suggested decreased TPC1 DNA replication correlated with decreased SOD3 expression. 
(I,J) FGF9 and BMP2 gene expression analysis suggested increased SOD3-driven expression in Thyroid MSCs 
transduced with SOD3 lentivirus and decreased growth factor expression in PTC MSCs transduced with RNAi 
SOD3 lentivirus compared to controls. The p-values (*p < 0.05, **p < 0.01, ***p < 0.001) were determined by 
two-tail independent samples t-tests.
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a sudden decrease in SOD3 expression24. Therefore, we have hypothesized that SOD3 benefits the initial phase of 
tumorigenesis at low (< 10-fold) RAS activation levels. Once SOD3 expression reaches non-physiological toxic 
levels, cancer cells are programmed to downregulate autocrine SOD3 production and instead stimulate stromal 
paracrine SOD3 secretion simultaneously with activation of stroma, as shown in Figs 3 and 4. Paracrine secretion 
of SOD3 then continues to support cancer cell growth (Fig. 5) and, correspondingly, decreases the affinity of 
cancer cells to tumor stroma by decreasing chemotactic cytokine expression (Fig. 6), allowing local intratumoral 
cancer cell migration.
In conclusion, based on the current data, PTC MSCs with a fibrotic fingerprint might function as a source 
of myofibroblasts. Importantly, clarification of the mechanisms of fibroblast activation could result in the dis-
covery of novel drug targets that are specific to thyroid cancer58 or cancer stroma. ROS, although forming a 
challenging molecular ensemble, control growth- and migration-related signaling routes that potentially contain 
drug targets. The current results suggest the autocrine-paracrine conversion of SOD3 expression, corroborating 
the growth supportive nature of the enzyme throughout the carcinogenic process. Thus, the identification of 
SOD3-coordinated signal transduction in tumor stroma and epithelial cancer cells may reveal small drug target 
molecules that could be used in combination therapy for the treatment of thyroid cancer.
Methods
Histological analysis. For histological analyses, papillary and follicular thyroid carcinoma samples were 
fixed in formalin, embedded in paraffin, and cut into 4–5 μ m sections with a microtome. Sections were de-waxed 
in xylene for 10 minutes, rehydrated by sequential immersion in decreasing ethanol concentrations. The sections 
were then stained with hematoxylin-eosin and analyzed using an optical microscope (Nikon ECLIPSE Ni, Nikon 
Instrument Europe B.V. Amsterdam, Netherlands). Two independent observers (F.C. and F.R.) examined the 
specimens.
Figure 6. Effect of SOD3 on TPC1 cancer cell migration. (A) TPC1 cancer cells migrated significantly faster 
towards Thyroid MSCs than PTC MSCs. Representative high-power fields from Matrigel shown. (B) Increased 
SOD3 expression in Thyroid MSCs significantly decreased TPC1 cell migration. Representative high-power 
fields from Matrigel are shown. (C) Reduced SOD3 expression reduced TPC1 cell migration toward PTC MSCs. 
Representative high-power fields from Matrigel are shown. (D) IL1α expression was significantly decreased in 
the PTC MSCs compared to the Thyroid MSCs. SOD3 over-expression in Thyroid MSCs significantly reduced 
IL1α mRNA synthesis compared to the Thyroid MSC control. (E) MCP1 mRNA expression was significantly 
decreased in PTC MSCs compared to Thyroid MSCs. SOD3 over-expression in the Thyroid MSCs significantly 
reduced MCP1 mRNA synthesis compared to the Thyroid MSC control. (F) IL8 mRNA expression was 
significantly decreased in the PTC MSCs compared to the Thyroid MSCs. SOD3 over-expression in the Thyroid 
MSCs did not affect IL8 expression. (G) MCP1 Western blot confirmed decreased MCP1 mRNA expression 
in the PTC MSCs compared to the Thyroid MSCs. (H) Flow cytometer analysis of IL8 expression confirmed 
decreased IL8 mRNA expression in the PTC MSCs compared to Thyroid MSCs. (I) Percentage of positive cells 
in the IL8 flow cytometer analysis. The p-values (*p < 0.05, **p < 0.01, ***p < 0.001) were determined by two-
tail independent samples t-tests.
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Isolation and culture of stromal cells. Thyroid mesenchymal stem/stromal cells (MSCs) were iso-
lated from non-malignant sites (Thyroid MSCs) and papillary thyroid cancer sites (PTC MSCs) of patients. 
De-identified thyroid tissue samples were obtained from patients who underwent thyroid surgery at the 
University of Wisconsin-Madison. The protocol was approved by the Health Sciences Institutional Review board 
(IRB) of the University and performed in accordance with the relevant guidelines and regulations59. Informed 
consent was obtained from all subjects according the requirements of University of Wisconsin-Madison protocol 
permission. Due to differences between individuals all analysis of the study were done comparing thyroid MSCs 
and PTC-MSCs of the same patient. Tumor tissue was washed several times with PBS, cut into small pieces, and 
then was plated in alpha MEM (Mediatech, Manassas, VA, USA) supplemented with 10% FBS (Hyclone, Logan, 
UT), non-essential amino acids (Mediatech) and L-alanine-l-glutamine (Life Technologies, Grand Island, NY, 
USA). After reaching 70–90% confluency, cells were harvested using TrypLE (Life Technologies) and passaged 
until reaching passage 4 before characterizing and using them in the study60. The MSCs were transduced with 
SOD3 and RNAi SOD3 lentivirus (MOI 10) (Dharmacon, Lafayette, Colorado, United States).
Differentiation assay. Cells seeded in dishes were stimulated with 10−6 M dexamethasone, 100 μg/ml 
3-isobutyl-1-methylxanthine, 50 μM indomethacin, and 10 μg/ml insulin (Sigma) for adipogenic differentiation, 
with 1 ng/ml recombinant human transforming growth factor-β1 (TGF-β1) (Sigma) for chondrogenic differenti-
ation and with 10−7 M dexamethasone, 10 mM β-glycerophosphate disodium, and 50 μg/ml ascorbic acid (Sigma) 
for osteogenic differentiation. Adipogenic differentiation was analyzed after 0.3% oil red O (Sigma) treatment, 
chondrogenic differentiation was analyzed after anti-human type II collagen MAb treatment, and osteogenic 
differentiation was analyzed after alizarin red S (Sigma) treatment60,61.
Flow cytometer assay. For the flow cytometry analysis, 100 000 cells were incubated in a 100 μ l volume 
with antibodies on ice. The cells were washed twice with PBS, resuspended in 500 μ l, filtrated, and analyzed.
Gene expression analysis. RNA was isolated using an RNeasy minikit (Qiagen, Hilden, Germany). The 
cDNA synthesis was performed by QuantiTect Reverse Transcription (Qiagen). SYBR Green PCR master mix 
(Applied Biosystems, Foster City, CA, USA) was used for qPCR. The primers are listed in the Supplementary 
Table T1.
Western blot analysis. The cells were homogenized in lysis buffer (50 mmol/L HEPES pH 7.5, 150 mmol/L 
NaCl, 10% glycerol, 1% Triton X-100, 1 mmol/L EGTA, 1.5 mmol/L MgCl2, 10 mmol/L NaF, 10 mmol/L sodium 
pyrophosphate, 1 mmol/L Na3VO4, 10 μ g approtinin/ml, and 10 μ g leupeptin/ml) (Sigma). The antibodies used 
were α MCP1 (Abcam, Cambridge, UK) and α -tubulin (Cell Signaling, Danvers, MA, USA).
Growth analysis. To characterize DNA replication, 10 mM bromodeoxyuridine (BrdU) (Roche, Basel, 
Switzerland) was added to the growth medium for 15 min. Subsequently, the cells were washed three times 
with PBS, fixed in 3% paraformaldehyde (Sigma) for 20 minutes at − 20 °C, washed three times with PBS, and 
stained using anti-BrdU antibody (Roche) primary antibody, FITC–conjugated secondary antibody (Jackson 
ImmunoResearch Laboratories Inc., West Grove, PA, USA), and Hoechst nuclear stain (Sigma).
Migration analysis. For the migration assay, 100 μ l of Matrigel (Corning, Corning, NY, USA) at 1 mg/ml was 
added to the migration chamber (8 microns, BD, San Jose, CA, USA) and allowed to stabilize at room temperature 
for 30 minutes. The chambers were moved to MSC cultures into 12-well plates, 50 000 TPC1 cells were added to 
the Matrigel and allowed to migrate for 24 hours at 37 °C. After incubation, the Matrigel was removed from the 
chamber, and the migrated cells were fixed with 7% paraformaldehyde (Sigma), washed with PBS, and stained 
with Cristal violet (Sigma). The migrated cells were counted from the high-power microscope fields.
Statistical analyses. The experiments were repeated at least three times. All results are expressed as the 
mean ± SD. The p-values (*p < 0.05, **p < 0.01, ***p < 0.001) were determined by two-tail independent samples 
t-tests.
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